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Objective. To characterize and compare the factors associated with tubulointerstitial inflammation (TII) and tubulointerstitial scarring, defined as interstitial fibrosis and/or tubular atrophy (IF/TA), in patients with lupus nephritis (LN).
Methods. We identified systemic lupus erythematosus patients who had renal biopsy results consistent with LN between 2005 and 2017. Clinical data were collected from medical records. Multivariable logistic regression models were fitted to assess factors associated with TII and with IF/TA (moderate-to-severe versus none/mild).
Results. Of 203 LN patients included, 41 (20%) had moderate-to-severe TII, 45 (22%) had moderateto-severe IF/TA, and 21 (10%) had both. Multivariable logistic regression models showed that moderate-to-severe TII was associated with a shorter disease duration, African American race, proliferative LN, and an estimated glomerular filtration rate (eGFR) of <60 ml/minute/ 1.73 m 2 at the time of biopsy. Hydroxychloroquine use was associated with significantly lower odds of moderateto-severe TII (odds ratio 0.27 [95% confidence interval 0.10-0.70], P = 0.008). Similar to TII, factors associated with moderate-to-severe IF/TA included proliferative LN and eGFR <60 ml/minute/1.73 m 2 at the time of biopsy. In addition, the presence of moderate-to-severe TII and older age was associated with moderate-to-severe IF/TA. None of the routinely available serologic markers-including anti-double-stranded DNA antibodies, anti-Ro/La antibodies, and low complement-were associated with tubulointerstitial damage.
Conclusion. The use of hydroxychloroquine was strongly associated with less inflammation, while the presence of TII, proliferative LN, and low eGFR were major determinants of tubulointerstitial scarring. Identifying modifiable factors is critical for the development of better preventive and therapeutic strategies with the goal of improving survival in patients with lupus-related kidney disease.
The majority of studies in lupus nephritis (LN) have focused primarily on identifying the mechanisms behind glomerular disease (1). However, glomerular-based measures of disease activity do not consistently predict adverse renal outcomes and perform poorly in identifying patients at the highest risk for renal failure (2) . A growing body of evidence indicates that indices of tubulointerstitial damage (TID) are better predictors of progression to renal failure than glomerular parameters (2-4). Both tubulointerstitial inflammation (TII) and tubulointerstitial scarring, namely interstitial fibrosis and tubular atrophy (IF/TA), strongly correlate with poor renal outcomes independent of the extent of glomerular damage (2, 3, 5, 6) .
TII is thought to precede IF/TA, but whether there are any differences in their clinical and serologic profiles is unknown. Unlike glomerular disease, complement levels and elevated titers of double-stranded DNA (dsDNA) antibodies have no correlation with TID (2,7). In Sj€ ogren's syndrome, the presence of extraglandular manifestations, including interstitial nephritis, is associated with high titers of anti-Ro/La antibodies (8) . In addition, previous studies have demonstrated potential renoprotective effects of hydroxychloroquine (HCQ) (9,10). However, no clinical studies to date have explored these associations specifically in TID.
Therefore, the objective of this study was to characterize and compare the factors associated with TII and IF/TA in patients with LN. We hypothesized that TII occurs earlier in the disease course and its presence could be influenced by medication use, whereas IF/TA would largely be determined by the degree of TII, renal impairment, and the presence of anti-Ro/La antibodies. Understanding the differences between TII and IF/TA is fundamental in the identification of risk factors for progression to permanent scarring and is an essential step in the development of novel preventive and targeted therapeutic strategies.
PATIENTS AND METHODS
This was a retrospective study conducted at Montefiore Medical Center, a community-based urban tertiary care center. The study was approved by the Institutional Review Board. We identified all adult and pediatric patients who fulfilled either the American College of Rheumatology (ACR) classification criteria (11) or the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus (SLE) (12) and had a renal biopsy between January 2005 and May 2017.
Tubulointerstitial indices were defined based on the National Institutes of Health activity and chronicity definitions as none/mild (involvement of <25% of the tubulointerstitium) or moderate (25-50%)-to-severe (>50%) (13) . The estimated glomerular filtration rate (eGFR) was calculated using the 4- (14) . Clinical, demographic, and laboratory parameters were compared, in parallel, between patients with and those without moderate-to-severe TII, and patients with and those without moderate-to-severe IF/TA. Sensitivity analyses were performed in the following subgroups: patients with proliferative nephritis only (excluding class I/II/V LN), patients >17 years old, and patients with mildly-to-moderately impaired eGFR (≥30 ml/minute/1.73 m 2 ).
RESULTS
Study sample. A total of 236 patients who had a kidney biopsy between January 2005 and May 2017 were identified. Ten patients who had biopsy findings not consistent with LN and 1 patient with class I LN and lupus podocytopathy with concurrent acute tubular necrosis were excluded. In addition, 22 patients had no clinical or histologic information available. Therefore, a total of 203 patients who fulfilled the ACR/SLICC SLE criteria and had complete TII and IF/TA data were included in the primary analysis.
Patient characteristics. Moderate-to-severe TII and moderate-to-severe IF/TA were found in 41 patients (20%) and 45 patients (22%), respectively. Moderate-to-severe IF/TA or TII was present in 65 (32%) of the 203 biopsy samples. Twenty-one patients (10%) had both moderateto-severe IF/TA and moderate-to-severe TII. Twenty-four patients (12%) had moderate-to-severe IF/TA alone with no significant TII, and 20 patients (10%) had moderateto-severe TII alone with no significant IF/TA. Twenty-one patients (47%) with moderate-to-severe IF/TA also had moderate-to-severe TII, compared to only 20 patients (13%) with no/mild IF/TA (P < 0.01) ( Table 1 ). The median serum creatinine level was 0.9 mg/dl (interquartile range [IQR] 0.7-1.4), and the median urine protein creatinine ratio was 2.0 mg/mg (IQR 0.96-4.90).
One hundred thirty-nine patients (70%) were receiving glucocorticoids at the time of biopsy. Seventyone patients (37%) had received immunosuppressive medications prior to biopsy; of these, 35 patients (53%) received mycophenolate mofetil. Less commonly used medications included azathioprine (29%), cyclophosphamide (5%), methotrexate (5%), and others (8%), including rituximab, tacrolimus, and intravenous immunoglobulin. Fifty-three percent of the patients were receiving HCQ at the time of biopsy.
Comparison of factors associated with moderateto-severe TII and moderate-to-severe IF/TA. Univariable analysis of factors associated with moderate-to-severe TII. Among the group of patients with moderate-to-severe TII, a higher proportion were African American (68%) compared to patients with no/mild TII (47%) (P = 0.01). Hypertension was present in 21 patients (54%) with moderate-to-severe TII and 55 patients (35%) with no/ mild TII (P = 0.03). There were no differences in the frequency of diabetes or Sj€ ogren's syndrome.
In terms of histologic features, proliferative LN (class III/IV AE V) was more common in patients with moderate-to-severe TII compared to those with no/mild TII (83% versus 57% [P = 0.02]). Classes I/II and V LN were seen accompanying moderate-to-severe TII in 2 (5%) and 5 (12%) biopsy specimens, respectively. With regard to laboratory findings, moderate-to-severe TII was associated with a lower eGFR at the time of biopsy (P < 0.001). The severity of TII was not associated with the degree of proteinuria, complement levels, or anti-dsDNA, anti-SSA/Ro, anti-SSB/La, anti-Sm/RNP, or antiphospholipid antibody levels.
At the time of biopsy, no differences between the groups were found with respect to the use of angiotensinconverting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), glucocorticoids, nonsteroidal antiinflammatory drugs (NSAIDs), or immunosuppressants. However, patients with no/mild TII were more likely to be receiving HCQ than patients with moderate-to-severe TII (60% versus 28% [P < 0.001]).
Univariable analysis of factors associated with moderate-to-severe IF/TA. Patients with moderate-to-severe IF/TA were significantly older at the time of biopsy 1802 LONDOÑO JIMENEZ ET AL Regarding medications, the use of immunosuppressants was more common in patients with moderateto-severe IF/TA compared to patients with none/mild IF/TA (49% versus 30% [P = 0.03]). There were no differences between the groups in the use of ACE inhibitors, ARBs, NSAIDs, or glucocorticoids, but unlike TII, HCQ was not associated with milder stages of IF/TA.
Multivariable analysis of the factors associated with TII and IF/TA. In a logistic regression model comparing moderate-to-severe TII to none/mild TII (Table 2) , factors associated with moderate-to-severe TII included a shorter disease duration, African American race, proliferative LN, and eGFR <60 ml/minute/1.73 m 2 at the time of biopsy. The adjusted association between history of hypertension and moderate-to-severe TII was only borderline significant (odds ratio [OR] 2.68 [95% confidence interval (95% CI) 0.99-7.03], P = 0.055). HCQ use was associated with significantly lower odds of moderate-to-severe TII (OR 0.27 [95% CI 0.10-0.70], P = 0.008). The magnitude of the association of these variables (expressed as ORs) remained very similar in the sensitivity analyses. The association of lower odds of TII with HCQ use, eGFR, and proliferative LN remained significant in all sensitivity analyses. The associations of TII with hypertension, disease duration, and race were not statistically significant in some of the sensitivity analyses due to loss of statistical power (data not shown).
Similar to TII, factors associated with higher odds of moderate-to-severe IF/TA in a logistic regression model included proliferative LN and eGFR <60 ml/minute/ 1.73 m 2 at the time of biopsy (Table 2 ). In the same logistic regression model, the presence of moderate-to-severe TII and older age was also associated with moderate-tosevere IF/TA. Use of immunosuppressive medications prior to biopsy was associated with a 6-fold increase in risk of moderate-to-severe IF/TA, suggesting the presence of more severe, refractory, and/or longstanding lupus activity at the time of biopsy. Disease duration, African American race, HCQ use, and hypertension were not associated with moderate-to-severe IF/TA. These findings remained unchanged in all of the sensitivity analyses (data not shown).
DISCUSSION
Multiple studies have recognized TID as a strong independent predictor of poor renal outcomes in LN (2,3,5,7). However, little is known about the factors that drive its development. In this hypothesis-generating study, we evaluated multiple clinical and serologic features that are routinely available to clinicians and compared the factors associated with TII and IF/TA in patients with LN.
In the current study, both moderate-to-severe TII and IF/TA were associated with proliferative LN and eGFR, as previously described (2, 6) . African American race was associated with moderate-to-severe TII. An increased frequency of TID has been previously reported in African Americans (13) . Whether the poor renal outcomes in African American patients with LN are partly * OR = odds ratio; 95% CI = 95% confidence interval (see Table 1 for other definitions).
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explained by an increased prevalence of TID deserves further study to better understand the significance of the underlying genetic and sociodemographic factors. Moderate-to-severe IF/TA or TII was present in 32% of the biopsies. In prior studies, moderate-to-severe TID was reported in 20-72% of kidney biopsy specimens from patients with SLE, the large variation in its prevalence owing to differences in staining methods and definitions of significant TID (2,3,7) . The prevalence of TID in the current study is similar to that in studies that have used routine light microscopy (3, 7) . The 72% prevalence of TID reported by Hsieh et al was based on CD45 staining which, although more sensitive, is not readily available in routine clinical practice (2) .
As expected, moderate-to-severe TII was more likely to occur early in the disease course, while IF/TA was largely determined by age, immunosuppressant use (as a proxy for disease severity and/or refractory disease), and the presence of TII. The consistency of many of these findings with previous studies supports the external validity and generalizability of our results.
The concept of inflammation leading to fibrosis is derived from the principles of tissue repair and from previous reports that have described a close association between tubulointerstitial inflammation and scarring (2,7). Our results are consistent with these observations and indicate that the presence of moderate-to-severe TII is independently associated with more advanced stages of IF/TA. The reversibility of TII was illustrated by Pagni et al in a study that examined the evolution of tubulointerstitial changes over time (5) . Consequently, there is a pressing need for early identification of patients with TII, in order to implement therapeutic strategies prior to the onset of irreversible scarring.
Several mechanisms by which glomerular disease can initiate TID have been proposed (15) . However, the fact that severe TID is also seen in isolation suggests that different pathways might be implicated in its pathogenesis (3, 15) . Immune complex deposition in the tubular basement membrane and in the peritubular capillaries is thought to arise from in situ antibody production and binding to locally available antigens (16) . This may occur early in the disease course, independently of glomerular immune complex deposition. Recent evidence suggests that the presence of tubular basement membrane complexes correlates with the severity of interstitial inflammation, clinical disease activity, and renal outcome (17) . Unfortunately, the presence or absence of these tubular deposits was not consistently reported for the biopsies included in the current study, and therefore we could not explore these associations.
Interestingly, HCQ was associated with a 73% decrease in the odds of moderate-to-severe TII. HCQ is known to interfere with Toll-like receptor (TLR) signaling. HCQ can inhibit the ligation of nucleic acid to TLRs by decreasing the endosomal acidification and/or directly binding to nucleic acids, masking their TLRbinding epitope (18) . Notably, previous experimental studies have demonstrated that participation of renal tubular TLRs in the pathogenesis of tubulointerstitial injury is instrumental in bridging the innate and adaptive immune responses responsible for kidney damage (19) . No clinical studies have evaluated the role of HCQ specifically in TII, but its association with higher rates of remission, fewer relapses, and reduced renal damage has been extensively described in LN (9, 10) .
In contrast to TII, we did not observe any association of HCQ with no/mild IF/TA. Given the retrospective nature of this study, these findings may have been affected by unmeasured confounders and lack of information about the duration of treatment with HCQ and medication compliance. Since IF/TA was associated with longer SLE duration at the time of biopsy, it is possible that patients with significant IF/TA were rapid progressors and HCQ was started too late in their disease course to alter its progression. In addition, the intricate mechanisms that ultimately lead to irreversible scarring remain unknown, and whether IF/TA can develop through noninflammatory cell death is also a consideration. Rigorous pharmacoepidemiologic studies are needed to ascertain potential benefits of HCQ in TID. In addition, the appropriate dosing regimen, as well as relative risks and benefits of long-term HCQ use, should be carefully assessed, considering concerns regarding ocular toxicity, especially in individuals with impaired kidney function (20) . Further studies are needed to examine whether HCQ use results longitudinally in a lower incidence of IF/TA.
Similar to previous studies, no association was seen between complement levels, anti-dsDNA, or degree of proteinuria and the severity of TII or IF/TA (2,7). A possible association of moderate-to-severe IF/TA with dual positivity for anti-Ro and anti-La antibodies, as shown by the results of our univariable analysis, should be investigated further.
In summary, this is the largest study, to date, comparing a comprehensive array of clinical and serologic factors associated with TII and IF/TA. Our results provide compelling evidence that routinely available serologic markers have no correlation with TID and highlight the need to identify novel biomarkers and targeted therapies. The findings of this study suggest that there is a window of opportunity to treat TII before the development of fibrosis. If validated in other patient populations, these results would strongly support the continued benefit of HCQ in lupus-related kidney disease even after initiation of immunosuppressive therapy to decrease tubular inflammation. Identifying the mechanisms by which HCQ decreases tubular inflammation and exploring the effects of interstitial immune complex deposition and peritubular capillaritis on cell death may result in the discovery of new biomarkers, aiding in the development of therapies that lead to ultimate improvement in renal survival.
